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Abstract
Background: Randomized clinical trials have shown the efficacy and safety of short-acting exenatide in patients
with type 2 diabetes mellitus (T2DM). The aim of this observational study was to investigate the effectiveness and
safety of exenatide twice a day in Korean patients with T2DM who are suboptimally controlled with oral hypoglycemic
agents.
Methods: This study was a post hoc analysis of multi-center (71 centers), prospective, observational, single-arm, post-
marketing study of short-acting exenatide 5 to 10 μg twice a day from March 2008 to March 2014 and analyzed those
who finished the follow-up over 20 weeks of medication. Changes of hemoglobin A1c (HbA1c), fasting plasma glucose
(FPG), and body weight values before and after exenatide treatment were analyzed. Adverse events and adverse drug
reactions were estimated in patients who were treated with exenatide at least once and for whom follow-up for safety
has been completed.
Results: After 20 weeks treatment with exenatide, mean HbA1c and body weight were significantly reduced from 8.4%
to 7.7% and from 83.4 kg to 80.2 kg, respectively (both p < 0.001). Subjects with higher baseline glucose and HbA1c
levels showed an independent association with a greater reduction in glucose level. In addition, short duration of
diabetes less than 5 years was an independent predictor for the improvement in glucose level. The majority of study
subjects showed a reduction in both body weight and glucose level (63.3%) after exenatide treatment. In terms of
safety profile, exenatide treatment was generally well-tolerated and the incidence of severe adverse event was rare
(0.8%). The gastrointestinal side effects were most common and hypoglycemia was reported in 1.7% of subjects.
Conclusion: In real clinical practice, 20 weeks treatment with short-acting exenatide was well tolerated and showed a
significant body weight and glucose reduction in Korean patients with T2D who are suboptimally controlled with oral
hypoglycemic agents.
Trial registration: ClinicalTirals.gov, number NCT02090673, registered 14 February 2008.
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Background
The prevalence of obesity and type 2 diabetes mellitus
(T2DM) is now increasing rapidly in Korea and Asian
countries [1–3]. However, glycemic control is not satisfac-
tory and the proportions of patients with reaching target
hemoglobin A1c (HbA1c) of <6.5% and <7.0% were 27%
and 45.6%, respectively in Korea [4]. In addition, different
side effects related to oral hypoglycemic agents including
weight gain and hypoglycemia [5] can cause a nonadher-
ence to medications and poor glycemic control [6]. There-
fore, there is still unmet need for another class of
hypoglycemic agent has both good efficacy and safety.
Exenatide is an incretin mimetic that activates
glucagon-like-peptide-1 (GLP-1) receptors. It mainly de-
creases postprandial plasma glucose level by stimulating
insulin secretion, suppressing glucagon secretion and
delaying gastric emptying in a glucose-dependent man-
ner [7, 8]. Numerous clinical studies in Western coun-
tries have shown the glucose-lowering efficacy of
exenatide monotherapy [9] and in combination with
other oral hypoglycemic agents including sulfonylurea,
metformin, and thiazolidinediones [10–13].
However, the pathophysiology of T2DM could be differ-
ent according to ethnicity and it was reported that β-cell
dysfunction is a main pathogenic mechanism for the devel-
opment of T2DM in Asian population but, a lesser degree
of insulin resistance compared with Caucasian [1, 14]. In
addition, glucose-lowering effect of GLP-1 analogues was
reported to be greater in Asian-dominant studies than in
non-Asian-dominant studies [15]. Furthermore, it has been
well known that results from real clinical setting are differ-
ent from those from randomized clinical trial (RCT) and
thus, observational studies are also necessary to evaluate
the effectiveness of health care [16].
Therefore, the aim of this study was to investigate the
effects of exenatide twice a day injection in a real clinical
practice on blood glucose level, body weight, and safety
profiles in obese Korean patients with T2DM who are
suboptimally controlled with oral hypoglycemic agents.
Methods
Study design
This is a post hoc analysis of multi-center (71 centers),
prospective, observational, single-arm, post-marketing
surveillance (PMS) study to evaluate the safety and effect-
iveness of short-acting exenatide (Byetta®), conducted
from March 2008 to March 2014, in patients with T2DM
(ClinicalTrials.gov, number NCT02090673). The investi-
gators’ decisions regarding the proper treatment and care
of the patient were made in the course of the normal clin-
ical practice; without blinding or randomization to par-
ticular comparator arms or therapies. In this study,
patients were enrolled for the collection of their data on
observations made during normal clinical practice such as
serum HbA1c, fasting plasma glucose (FPG), body weight,
medical history, and adverse events.
Study populations and treatments
The patient population for this study consisted of Ko-
rean patients who were at least 18 years old, diagnosed
with T2DM, and were treated with short-acting exena-
tide in an ambulatory care setting according to the ap-
proved label. Patients were excluded from the study for
any of the following reasons; simultaneously participat-
ing in a different study that includes a treatment inter-
vention and/or an investigational drug, being pregnant
or having intentions to be pregnant within the duration
of the study, and being contraindicated for short-acting
exenatide. Investigators have ensured that patients, or, in
those situations where consent could not be given by pa-
tients, their legally acceptable representatives, are clearly
and fully informed about the purpose of the study, po-
tential risks, the patient’s rights and responsibilities
when participating in this study.
All patients were initially injected using 5 μg of short-
acting exenatide twice daily. After 1 month of injection
5 μg, the exenatide dosage was intended to increase to
10 μg twice a day under the decision of the physician. The
previous antidiabetic medications were maintained during
the periods of exenatide treatment. Life style modification
therapy and education for not only diet but also exercise
were combined in parallel with medications.
Effectiveness assessment
Based on electronic database of the study with high con-
fidentiality, the patients were rearranged for the purpose
of reanalysis settings (Fig. 1). The variables for the effect-
iveness of short-acting exenatide after 20 weeks of treat-
ment were changes in HbA1c, FPG, body mass index
(BMI), and body weight. Total 1269 patients who re-
ceived more than one-time injection of exenatide were
reviewed. Of these, 181 and 334 patients dropped out
within 8 and 20 weeks, respectively. Thus, 754 patients
continued short-acting exenatide over 20 weeks and
were reviewed for safety analysis. With additional exclu-
sion of 32 patients due to lack of clinical data, a final
number of 722 patients were reviewed for effectiveness
analysis. Among them, 619 patients who measured
HbA1c level both at baseline and 20-week endpoint
were analyzed for HbA1c. In the same way, 540, 655,
and 674 patients were analyzed for FPG, BMI, and body
weight, respectively. Patients were also defined by 2-
dimensional quadrant allocation according to the abso-
lute change in HbA1c and body weight in the same
picture.
Reanalysis for the effectiveness was conducted using
stratified categorization with the responsiveness for the
short-acting exenatide. In the first stratum by median
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value of HbA1c reduction, patients were divided into
two groups with 0.6% HbA1c reduction. The second
stratum used the absolute value as target HbA1c as
7.5%. As known in various randomized controlled trials,
mean HbA1c at the end of treatment, the primary end-
point in the majority of studies, was decreased by 0.79
to 1.75% (the median value across these large studies
was 1.11%) [17]. The baseline HbA1c of our study was
8.4% and we assumed responder as patients who would
reach HbA1c level at 7.5% after 20 weeks of exenatide
treatment. On the other hands, the third stratum was
applied by the mean change percentage of HbA1c from
baseline which was calculated as 9.8% as percentage.
The mean HbA1c level was 8.40% before treatment and
7.56% after exenatide over 20 weeks. The absolute differ-
ence was 0.84%, which was re-calculated as 9.8% as per-
centage compared to basal mean HbA1c level.
Safety assessment
Patients who were participating the study could reject or
withdraw the continuation of treatment or the study
with the reason of follow-up lost, adverse events, pa-
tient’s decision, or physician’s decision. If a patient
discontinued the treatment during the study, the pa-
tients were contacted to collect all adverse events infor-
mation and reasons why they want to stop the
treatment. All relevant information was captured by data
form. Patients who were discontinued from study were
included to safety population if they had taken at least
one dose of exenatide. We calculated the discontinu-
ation rate due to any adverse events. Adverse events and
serious adverse events which were recorded in electronic
case report form were recoded and reanalyzed according
to the current routine classification. For the serious ad-
verse events, we reviewed the patient record and re-
vealed the diagnosis of them.
Statistical analysis
All statistical analysis was performed with SAS (version
9.4, SAS Institute, Cary, NC, USA) for the numerics, and
NCSS (version 11, NCSS company, Kaysville, UT, USA)
for the graphics. For effectiveness analysis, missing
values was imputed using the last observation carried
forward methods. Baseline characteristics were shown in
descriptive statistics such as mean and standard devi-
ation for continuous data, or frequency and percentage
1,269 patients were reviewed for safety,
given short-acting exenatide
1,088 patients,
continue short-acting exenatide during 8 weeks
754 patients,
continue short-acting exenatide over 20 weeks
181 patients, drop out 
67 patients due to adverse event
105 patient due to other reason
9 patients due to unknown reason
334 patients, drop out 
8 weeks
20 weeks
49 patients due to adverse event
201 patient due to other reason
84 patients due to unknown reason
722 patients were reviewed for effectiveness
32 patients, excluded in effectiveness analysis
due to lack of clinical data
619 patients,
For HbA1c
540 patients,
For FPG
655 patients,
For BMI
674 patients,
For body weight
1,269 patients,
For safety
Fig. 1 Study flow diagram demonstrating analysis population
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for categorical data. Safety analysis was also summarized
descriptively.
Clinical factors which could affect the HbA1c reduc-
tion between responder and non-responder groups were
analyzed using chi-square test in 3 different strata. We
performed multivariate logistic regression test to adjust
the potential variables for the HbA1c reduction in each
stratum. To confirm the correlation between changes of
HbA1c and body weight, scattered graph was rendered
and correlation coefficient was calculated. If p-value is
less than 0.05, it was considered statistically significant.
Results
Baseline clinical and laboratory characteristics of
participants
Of the total 1269 patients who received more than one-
time injection of exenatide twice a day, data retrieved
from 754 patients who completed 20 weeks treatment
with exenatide were analyzed for the safety profiles
(safety analysis set). Among the 754 participants, 619 pa-
tients who measured HbA1c level both at baseline and
20-week endpoint were analyzed for the effectiveness
(effectiveness analysis set).
Based on the safety analysis set (n = 754), the mean
age and BMI of study subjects were 48.8 years and
31.2 kg/m2, respectively. 34.0% of the subjects were
men. Approximately one third of the study subjects had
a family history of diabetes and duration of diabetes was
7.7 years. At baseline, mean HbA1c and FPG level were
8.4% and 164.3 mg/dL, respectively (Table 1).
Clinical and laboratory variables affecting glucose
lowering effectiveness
In the current study, mean dosage of exenatide was
16.0 μg/day. A significant reduction in FPG (15.12 mg/dL)
and HbA1c (−0.75%) levels from baseline were observed
over 20-week of exenatide treatment. To determine
glucose-lowering effect of exenatide, we used three differ-
ent criteria to define responder to exenatide treatment.
The characteristics of responders by three definitions as
stratum are shown in Table 2. Using a responsiveness
based on absolute value of HbA1c reduction ≥0.6%, sub-
jects with optimal response to exenatide had significantly
higher baseline FPG and HbA1c levels than those with
suboptimal response to exenatide treatment. In addition,
men and subjects with short duration of diabetes less than
5 years were more likely to improve in glucose level with
exenatide treatment with significance. However, age and
BMI did not affect glucose-lowering effectiveness of
exenatide treatment. Using a responsiveness based on
achievement in HbA1c ≤ 7.5% at 20-week endpoint, sub-
jects who reached the target HbA1c had statistically lower
baseline FPG and HbA1c levels. The subjects with short
duration of diabetes showed significantly better glucose
control. Using a responsiveness based on achievement in
≥9.8% of baseline HbA1c, subjects with optimal response
to exenatide had significantly higher baseline FPG and
HbA1c levels. Similar to analysis stratum 1, subjects with
short duration of T2DM were more likely to improve in
glucose level with exenatide treatment with significance.
Before the initiation of exenatide, patients who had been
taking 2 oral antidiabetics showed relatively higher pro-
portion in responder in stratum classified by the changes
from baseline. However, in the analysis of target HbA1c as
7.5%, patients with 0 or 1 antidiabetics demonstrated bet-
ter achievement proportion. To determine which clinical
and laboratory variables were independently associated
with glucose-lowering effectiveness of exenatide, multi-
variate logistic regression analysis was used. As a result,
higher baseline FPG and HbA1c levels were independently
associated with greater reduction in glucose level after
Table 1 Baseline characteristics of the study subjects
Baseline demographics Patients who completed at least 20 weeks
of short-acting exenatide (n = 754)
Age (years) 48.76 ± 11.44
Sex
Male 256 (33.95)
Female 498 (66.05)
BMI (kg/m2) 31.15 ± 4.68
Baseline HbA1c (%) 8.40 ± 1.74
Baseline FPG (mg/dL) 164.26 ± 62.10
Daily dose (μg) 15.96 ± 3.46
Diabetes family history
No 491 (65.12)
Yes 263 (34.88)
Duration of diabetes
(months)
92.66 ± 79.42
Concurrent disease
No 115 (15.25)
Yes 639 (84.75)
Antidiabetic medication
0 or 1 medication 260 (34.48)
2 or more medications 494 (65.52)
Kind of antidiabetic medications
Metformin 672 (89.12)
Sulfonylureas 494 (65.52)
Thiazolidinediones 17 (2.25)
Other concomitant medication
No 80 (10.61)
Yes 674 (89.39)
Values are presented as mean ± standard deviation of the mean or the
number with percentage
Abbreviations: BMI Body Mass Index, HbA1c Hemoglobin A1c, Fasting
plasma glucose
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exenatide treatment. In contrast, subjects with longer dur-
ation of diabetes more than 5 years showed an inverse as-
sociation with the improvement in glucose control
(Table 3).
Efficacy of Exenatide for HbA1c level and weight changes
We next determined the weight change with exenatide
treatment. After 20 weeks treatment with exenatide
twice a day, body weight was significantly reduced from
83.4 kg to 80.2 kg (p < 0.001, Fig. 2). The majority of
study participants showed a reduction in both body
weight and glucose level after exenatide treatment
(63.3%) whereas, only 3.8% of subjects did not respond
to exenatide treatment in both body weight and glucose
aspects. Interestingly, 22.0% of subjects showed a weight
reduction but, aggravation in glucose control and 11.0%
Table 2 Clinical factors which may affect HbA1c reduction after treatment with short-acting exenatide over 20 weeks
HbA1c reduction ≥0.6% HbA1c <7.5% HbA1c reduction ≥9.8% from baseline
Yes (n = 316) No (n = 303) P Yes (n = 346) No (n = 273) P Yes (n = 263) No (n = 356) P
Age (years)
≥ 50 24.4 (151) 24.9 (154) 0.45 27.1 (168) 22.1 (137) 0.69 20.0 (124) 29.2 (181) 0.36
< 50 26.7 (165) 24.1 (149) 28.8 (178) 22.0 (136) 22.5 (139) 28.3 (175)
Sex (%)
Male 19.9 (123) 13.6 (84) 0.003 19.7 (122) 13.7 (85) 0.28 17.3 (107) 16.2 (100) 0.001
Female 31.2 (193) 35.4 (219) 36.2 (224) 30.4 (188) 25.2 (156) 41.4 (256)
BMI (kg/m2)
≥ 30 31.6 (184) 27.2 (158) 0.13 32.8 (191) 26.0 (151) 0.69 25.8 (150) 33.0 (192) 0.41
< 30 19.6 (114) 21.7 (126) 23.7 (138) 17.5 (102) 16.7 (97) 24.6 (143)
HbA1c (%)
≥ 8.5 30.7 (190) 13.6 (84) <0.001 12.1 (75) 32.2 (199) <0.001 25.5 (158) 18.7 (116) <0.001
< 8.5 20.4 (126) 35.4 (219) 43.8 (271) 12.0 (74) 17.0 (105) 38.8 (240)
FPG (mg/dL)
≥ 160 27.9 (137) 15.0 (74) <0.001 17.1 (84) 25.8 (127) <0.001 23.0 (113) 19.9 (98) <0.001
< 160 23.6 (116) 33.5 (165) 41.1 (202) 16.1 (79) 19.7 (97) 37.4 (184)
Daily dose of exenatide (μg/day)
≥ 15 36.5 (226) 33.9 (210) 0.55 39.6 (245) 13.3 (82) 0.82 31.3 (194) 39.1 (242) 0.12
< 15 14.5 (90) 15.0 (93) 16.3 (101) 30.9 (191) 11.2 (69) 18.4 (114)
Family history of diabetes (%)
No 28.4 (135) 24.2 (115) 0.96 29.1 (138) 23.6 (112) 0.86 23.6 (112) 29.1 (138) 0.68
Yes 25.5 (121) 21.9 (104) 26.5 (126) 20.8 (99) 22.1 (105) 25.3 (120)
Duration of diabetes (years)
≥ 5 29.4 (158) 32.0 (172) 0.040 26.3 (141) 35.2 (189) <0.001 23.8 (128) 37.6 (202) 0.023
< 5 22.0 (118) 16.6 (89) 26.8 (144) 11.7 (63) 18.8 (101) 19.7 (106)
Concurrent disease (%)
No 6.8 (42) 6.5 (40) 0.97 7.9 (49) 5.3 (33) 0.45 5.8 (36) 7.4 (46) 0.78
Yes 44.3 (274) 42.5 (263) 48.0 (297) 38.8 (240) 36.7 (227) 50.1 (310)
Number of previous antidiabetic medication (%)
0 or 1 15.5 (96) 19.1 (118) 0.025 24.2 (150) 10.3 (64) <0.001 12.8 (79) 21.8 (135) 0.042
2 35.5 (220) 29.9 (185) 31.7 (196) 33.8 (209) 29.7 (184) 35.7 (221)
Other concomitant medication (%)
No 3.7 (23) 5.2 (32) 0.15 5.3 (33) 3.6 (22) 0.52 3.4 (21) 5.5 (34) 0.50
Yes 47.3 (293) 43.8 (271) 50.6 (313) 40.6 (251) 39.1 (242) 52.0 (322)
Abbreviations: BMI Body Mass Index, HbA1c Hemoglobin A1c,, Fasting plasma glucose
Chi-square test
Data are expressed as percentage (number)
Body mass index, fasting plasma glucose, family history of diabetes, and duration of diabetes were determined in 582, 492, 475, and 537 subjects, respectively
Hwang et al. BMC Endocrine Disorders  (2017) 17:68 Page 5 of 9
of subjects showed an improvement in glucose control
despite of weight gain (Fig. 3).
Tolerability and adverse events of Exenatide
Regarding the tolerability of exenatide, 181 and 334 sub-
jects among total 1269 patients discontinued the injec-
tion of exenatide twice a day within 8-week and between
8 and 20 weeks of study period. Of 1269 patients, 116
patients stopped the injection of exenatide for adverse
events. The final drop-out rate of short-acting exenatide
just due to the adverse events was 9.14%. Within 8 weeks
of medication, discontinuation rate due to adverse
events was 5.3% (67 patients out of 1269 patients). Con-
secutively, the discontinuation rate due to adverse events
between 8 and 20 weeks of medication showed 4.5% (49
patients out of 1088 patients) (Fig. 1).
Based on the safety analysis set (n = 754) who com-
pleted 20 weeks treatment with exenatide, severe adverse
event was very rare (0.8%) but 173 cases (22.9%) of ad-
verse events were reported. The gastrointestinal side ef-
fects, mostly nausea, were the most common side effect
and hypoglycemia was reported in 1.7% of subjects
(Table 4). When it comes to serious adverse events, 6
cases were cholecystitis, hyperglycemia, rotator cuff syn-
drome, tendon disorder, diabetic skin ulcer, and cellulitis.
Discussion
To overcome many shortcomings of the classic anti-
diabetic drugs (ADDs) such as hypoglycemia and weight
Table 3 Adjusted potential variables for the prediction of the HbA1c responses according to the stratified classification
HbA1c reduction ≥0.6% HbA1c <7.5% HbA1c reduction ≥9.8% from
baseline
OR (95% CI) P OR (95% CI) P OR (95% CI) P
Male sex 1.47 (0.94–2.29) 0.09 Not determined 1.40 (0.90–2.15) 0.13
HbA1c ≥8.5% 3.13 (1.95–5.04) <0.001 0.13 (0.08–0.22) <0.001 2.36 (1.48–3.77) <0.001
FPG ≥160 mg/dL 1.60 (1.01–2.54) 0.047 0.58 (0.35–0.97) 0.037 1.47 (0.93–2.34) 0.10
Duration of diabetes ≥5 years 0.997 (0.995–1.000) 0.053 0.994 (0.991–0.997) <0.001 0.997 (0.994–1.000) 0.043
Number of previous antidiabetic medication (2 vs. 0 or 1) 1.07 (0.67–1.71) 0.79 0.91 (0.52–1.58) 0.74 1.28 (0.80–2.05) 0.31
Abbreviations: OR odd ratio, HbA1c Hemoglobin A1c, FPG Fasting plasma glucose
Multivariate logistic regression test; References of dependent variables in each stratum, Group 2, Group B, and group II, respectively
A B
C D
Fig. 2 Changes of clinical findings from before to after short-acting exenatide over 20 weeks. (A) Hemoglobin A1c (HbA1c) level (n = 619), (B)
Fasting plasma glucose (FPG) level (n = 54), (C) Body mass index (BMI) (n = 655), (D) Body weight (n = 674)
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gain etc., incretin-based drugs including GLP-1 analogues
and dipeptidyl peptidase-4 (DPP4) inhibitors have been
progressively developed and been regarded as a recom-
mended drug for glycemic control in patients with T2DM
[8]. Furthermore, by overcoming drug delivery system,
long-acting GLP-1 s are now gaining popularity as innova-
tive drug in managing the subjects with T2DM. Because of
plentiful accumulated reports on exenatide, the first-in-
class drug of GLP-1 analogue, the debate on clinical rele-
vance of exenatide might be little. However, the clinical
relevance on effectiveness and safety are reported mainly
under the designed trials with the statistical expectations.
We hypothesized that reluctance might remain to
generalize the results of RCTs retrieved from a specific seg-
ment of the population to broader population or real prac-
tice [16, 18], and that it might be more important to both
patients and physicians in managing the diabetes after iden-
tifying the results of RCTs with those of observation studies
(OSs) retrieved from routine care. Based on these hypoth-
eses, we aimed this study for investigating clinical effective-
ness and safety of exenatide twice a day in real-life setting.
From this prospective, 20-week observational, phase 4
PMS study with short-acting exenatide twice a day in
Korean patients with T2DM, we demonstrated 3 main
findings. First, exenatide twice a day significantly in-
duced HbA1c and weight reduction in real clinical prac-
tice. Second, higher baseline glucose level and short
duration of diabetes were independent predictor for
good glycemic control after exenatide treatment. Third,
adverse events of exenatide in real-life setting are similar
to those of RCTs [19].
With respect to study design, this analysis retrieved
from the prospective, observational, PMS study. RCTs
and OSs have both benefits and drawbacks reciprocally,
which should be interpreted with balanced stance.
Briefly, the inclusion and exclusion criteria of RCTs tend
to be defined narrowly to conduct either the regulatory
requirements in drug trials or the specific aims targeting
selected population. The characteristics of patients who
participate in the clinical trials are to be more concerned
on their health status and care by health providers, and
compliant with the drugs. In these regards, they might
provide limited usefulness on the effectiveness and safety
of a drug to generalize to the real world practice. In con-
trast, the design of PMS OSs in everyday practice setting
is able to cover a broader population without stringent
inclusion/exclusion criteria, and characteristics of pa-
tients. Furthermore, it also provides valuable information
on the physician’s preference and ideas [20]. These un-
met need of RCTs but complemented by OSs as part of
routine care might be important to both patients and
health providers for treatment decisions.
With respect to the glycemic effectiveness of exenatide
twice a day in real-life setting, exenatide improved
Fig. 3 Distribution of patients for the relation between Hemoglobin
A1c (HbA1c) and body weight before and after treatment with
short-acting exenatide over 20 weeks. Red line represents regression
for HbA1c according to body weight change, which shows the
correlation coefficient as 0.00357 closed to 0. It means that there is
rare correlation between changes HbA1c and body weight
Table 4 Summary of adverse events for the treatment with
short-acting exenatide
Adverse events Number of patients
(n = 754)
Number of
events
Any adverse events 173 (22.94%) 246
Serious adverse events 6 (0.80%) 6
Gastro-intestinal adverse events 116 (15.38%) 154
Nausea 93 (12.33) 100
Vomiting 19 (2.52%) 19
Dyspepsia 8 (1.06%) 8
Constipation 7 (0.93%) 7
Diarrhoea 5 (0.66%) 5
Others 13 (1.72%) 15
Metabolic and endocrine adverse
events
22 (2.92%) 23
Hypoglycaemia 13 (1.72%) 14
Others 9 (1.19%) 9
Neuropsychologic adverse events 25 (3.32%) 29
Dizziness 7 (0.93%) 7
Headache 6 (0.80%) 6
Anorexia 5 (0.66%) 5
Others 9 (1.19%) 11
Cardiovascular adverse events 5 (0.66%) 5
Respiratory system adverse events 3 (0.40%) 3
Urinary system adverse events 1 (0.13%) 1
Musculo-skeletal or generalized
adverse events
16 (1.21%) 18
Others 11 (1.46%) 13
Data are expressed as percentage (number)
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glycemic control through up-regulating β-cells and
down-regulating α-cells residing in pancreatic islets. In
recent meta-analysis, short-acting exenatide twice a day
was effective in reducing HbA1c (− 0.61% for 5 μg, and
– 0.83% for 10 μg) compared with placebo in patients
with T2DM [21]. Furthermore, Kim et al. reported that
GLP-1 analogues including exenatide, and liraglutide
lowered HbA1c more in Asian-dominant studies than in
non-Asian-dominant studies [15]. In this OS, there was
significant reduction in both FPG (−15.12 mg/dL), and
HbA1c (−0.75%) from baseline. Regarding the responders
to ADDs, the conventional definitions of responders
might be one of the two analyses, the absolute HbA1c
change from baseline after treatment, or achievement in a
target HbA1c level [22]. Based on this report [22], we ana-
lyzed the glycemic effectiveness or responder in three
ways; achievement in 1) absolute value of HbA1c reduc-
tion ≥0.6%, 2) HbA1c ≤ 7.5%, and 3) ≥ 9.8%, of baseline
HbA1c. Using effectiveness or responder definitions based
on absolute reduction ≥0.6% HbA1c, achievement in
HbA1c ≤ 7.5%, and ≥9.8%, of baseline HbA1c reduction,
the percentage rate in responders were 51.1%, 55.9% and
42.5%, respectively. Regardless of definitions of responder,
duration of diabetes, baseline FPG and HbA1c, and num-
bers of ADDs were significantly different between the re-
sponders and non-responders. However, the rest two
variables are different according to the definitions of re-
sponder. Regarding clinical characteristics predicting in
responsiveness of exenatide, shorter duration of diabetes
was the only predictive variable for responders in glucose
control. Those who had higher baseline HbA1c, a critical
variable of potential confounder, showed the more reduc-
tion in absolute HbA1c and percentage of baseline
HbA1c, but the lower achievement in target HbA1c. Pre-
vious reports also showed the consistent results that the
higher baseline HbA1c was related to the more HbA1c re-
duction but less probability of achievement in glycemic
goal [22–24]. Regarding glycemic effectiveness in response
to weight change, treatment with exenatide twice a day
significantly reduced - 3.22 Kg body weight. Of the partici-
pants who completed the study, 63.3% (n = 369) experi-
enced the both benefits of GLP-1 analogues on HbA1c
reduction and weight loss. Those who got none benefits of
exenatide were just 3.77%. In the study, BMI did not affect
glucose-lowering effect of exenatide. In one study which
was aiming to investigate metabolic outcomes in patients
with type 2 diabetes treated with exenatide, the response
in HbA1c reduction was independent of baseline weight,
and BMI [25]. Also, most subjects enrolled in this PMS
study showed high BMI due to Korean insurance policy
during the study period. This may have influenced the
outcome of the study.
With respect to the adverse events of exenatide, of 181
participants who discontinued exenatide injection, 37%
ones failed to continue on exenatide within 8 weeks. Of
334 participants who discontinued exenatide injection
between 8 weeks and 20 weeks, 14.7% of subjects dis-
continued on exenatide injection. Taken together, of
1269 subjects retrieved from safety analysis set, 161
(9.1%) reported to stop the exenatide injection. Those
who were analyzed for effectiveness analysis set
(n = 754) at 20 weeks in this PMS OS, 22.9% subjects re-
ported any adverse events. Based on this finding, caution
should be paid to the patients’ tolerability.
The strengths of this study are the large sample num-
ber and the real-world clinical practice setting with pa-
tients of only Asian ethnic background. It, however, also
has important weaknesses. This study did not provide
the laboratory data to evaluate the pancreatic β-cell
functions and peripheral insulin sensitivity which are the
key pathophysiologic factors in the development and
progress of T2DM. The clinical implications of duration
of diabetes, baseline FPG and HbA1c, and numbers of
ADDs which were different between the responders and
non-responders might be explained in these assessments.
Second, in the balanced stance of both studies design of
RCTs and OS, this study might remain observer and se-
lection bias which are reflected by not scientific milieu
but socio-economic one. Underreporting also occurred
especially in drug adverse events. A final major limita-
tion is the drop out data from missing data and adher-
ence to physicians’ orders.
Conclusions
In conclusion, the results of the study of real-life clinical
practice in Korea demonstrate that, in Korean subjects
with T2DM, exenatide twice a day resulted significant
reduction in glycemic control and relative tolerance in
Korean patients with T2DM in real-world clinical
setting.
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